A. Knoop

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

A. Laenkholm, M. Andersson, E. Santoni-Rugiu, 2012 .

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

A. Laenkholm, M. Andersson, E. Santoni-Rugiu, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors.

M. Ewertz, M. Jensen, L. Eckhoff, 2015, European journal of cancer.

Abstract P4-10-18: Changes in tumour infiltrating lymphocytes during neoadjuvant endocrine therapy and possible clinical implications for guiding therapy

A. Laenkholm, M. Jensen, B. Ejlertsen, 2020 .

TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D).

E. Balslev, K. Nielsen, B. Rasmussen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

L. Zelek, A. Ballestrero, L. Fallowfield, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.